| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4511-5MG | Ruxolitinib | 5mg | $137.00 | |
| GBM-4511-25MG | Ruxolitinib | 25mg | $315.00 |
| Bioassays Specification | |
| Bio-Activity | JAK inhibitor |
| Chemical Name | βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile |
| Function / Pharmacology | Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1 Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4 Clinically useful cancer chemotherapeutic. |
| CAS# | 941678-49-5 |
| MW | 306.37 |
| Molecular Formula | C17H18N6 |
| Solubility | Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636 2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med., 23 1072 4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget, 8 34687 |
| Antibody Specification | |
| Alternate Names | INCB 018424 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | JAK inhibitor |
| Chemical Name | βR-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile |
| Function / Pharmacology | Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively.1 Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM).2 Inhibits the proinflammatory secretome of senescent cells.3 The JAK1 S646P mutant is highly sensitive to ruxolitinib.4 Clinically useful cancer chemotherapeutic. |
| CAS# | 941678-49-5 |
| MW | 306.37 |
| Molecular Formula | C17H18N6 |
| Solubility | Soluble in DMSO (up to 28 mg/ml) or in Ethanol (up to 15 mg/ml with warming). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Verstovsek et al. (2009), Therapeutic potential of JAK2 inhibitors; Hematology Am. Soc. Hematol. Educ. Program, 2009(1) 636 2) Quintas-Cardama et al. (2010), Preclinical characterization of the selective JAK1/2 inhibitor INCB01824: Therapeutic implications for the treatment of myeloproliferative neoplasms; Blood, 115 3109 3) Farr et al. (2017) Targeting cellular senescence prevents age-related bone loss in mice; Nat. Med., 23 1072 4) Li et al. (2017) Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia; Oncotarget, 8 34687 |
| Antibody Specification | |
| Alternate Names | INCB 018424 |
| Protein Specification | |
| Purity | >98% |
